Advanced Search

Study Preview



Study Title and Description

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Author Grebely J., Conway B., Cunningham EB., Fraser C., Moriggia A., Gane E., Stedman C., Cooper C., Castro E., Schmid P., Petoumenos K., Hajarizadeh B., Marks P., Erratt A., Dalgard O., Lacombe K., Feld JJ., Bruneau J., Daulouede JP., Powis J., Bruggmann P., Matthews GV., Kronborg I., Shaw D., Dunlop A., Hellard M., Applegate TL., Crawford S., Dore GJ.
Country The Kirby Institute, UNSW Sydney, Wallace Wurth Building, UNSW NSW 2052, Australia. Electronic address: jgrebely@kirby.unsw.edu.au.
Year 2018
Numbers Pubmed ID: 30384028

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.